Abstract PR014: Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational combination strategies in pancreatic cancer

作者
Wungki Park,Shilpa Kadam,MPH Anup Kasi MD,Teresa Mercade Macarulla,Christos K Fountzilas,Makoto Ueno,Takeshi Saito,Stanley C. Gill,Erica Tong,Hui Yang,Sebastian Gloskowski,Joshua Sallin,Gustave Ronteix,Fanny Jaulin,Hisaki Fujii
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (18_Supplement_2): PR014-PR014
标识
DOI:10.1158/1538-7445.pancreatic26-pr014
摘要

Abstract Background: KRAS G12D is a prevalent oncogenic driver in PDAC, which has a high unmet need due to few effective targeted therapies. Setidegrasib, a novel KRAS G12D-targeted protein degrader, eliminates the oncogenic driver to suppress downstream signaling and induce tumor cell death. Early clinical activity was reported in an ongoing Phase 1 study (NCT05382559). We present exploratory analyses to characterize the biological activity of setidegrasib and inform biomarker-driven combination strategies. Methods: Patients with locally advanced KRAS G12D-mutant PDAC and prior standard therapies received 140–800 mg setidegrasib monotherapy IV QW. Longitudinal tumor biopsies and plasma were analyzed by transcriptomic profiling to assess KRAS-MAPK signaling, tumor cell states, and the tumor microenvironment (TME). ctDNA analyses enabled real-time monitoring of tumor burden and molecular response. Target engagement was assessed by KRAS G12D IHC, downstream pharmacodynamic effects by tumor gene expression profiling, and TME by multiplex immunofluorescence. Parallel patient-derived organoid (PDO) studies and AI modeling evaluated resistance mechanisms and combination strategies. Results: Data cutoff was November 10, 2025. Samples from 124 patients with KRAS G12D-mutant PDAC (10–90mg=26; 140mg=5; 200mg=12; 300mg=30; 450mg=10; 600mg=31; 800mg=10) were analyzed. Setidegrasib demonstrated durable on-target activity, including robust KRAS G12D degradation (median 95.5%) and downstream MAPK suppression. Transcriptomic and proteomic analyses confirmed differential inhibition of MYC, RAS, and cell-cycle signaling in responders versus non-responders. Baseline tumors from non-responders harbored more co-mutations than responders (NR:R; TP53, 93:87%; SMAD4, 29:0%; CDKN2A, 50:20%; MTAP, 21:0%; EGFR, 7:0%). Major molecular responses were observed in 90% (9/10) of responders by C2D1, marked by a >90% reduction in KRAS G12D ctDNA VAF. Distinct ctDNA trajectories of response and resistance were observed. Progressors exhibited epithelial-mesenchymal transition programs, indicating adaptive tumor plasticity and resistance evolution. Responders demonstrated host anti-tumor immune activation characterized by apoptotic tumor cell death, GZMB+ CD8+ T-cell-mediated tumor clearance through Fas/FasL interactions, and IFN-γ signaling, followed by immune exhaustion with increased PD-L1 expression. PDO studies and AI modeling predicted clinical outcomes and biological activity, and further demonstrated improved outcomes with setidegrasib plus FOLFIRINOX, supporting a rational combination strategy. Conclusions: Setidegrasib demonstrated promising activity in PDAC with robust target engagement, durable pathway suppression, and TME modulation. Translational analyses identified a distinct, targetable resistance landscape, supporting continued development of setidegrasib in combination with FOLFIRINOX for PDAC (NCT07409272) to enhance clinical benefit. Citation Format: Wungki Park, Shilpa Kadam, Anup Kasi, Teresa Macarulla, Christos Fountzilas, Makoto Ueno, Takeshi Saito, Stanley C. Gill, Erica Tong, Hui Yang, Sebastian Gloskowski, Joshua Sallin, Gustave Ronteix, Fanny Jaulin, Hisaki Fujii. Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational combination strategies in pancreatic cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr PR014.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小绵羊发布了新的文献求助10
2秒前
标致的如娆完成签到,获得积分10
3秒前
3秒前
细心的安雁完成签到,获得积分10
4秒前
水星逃逸完成签到 ,获得积分10
4秒前
安凉完成签到 ,获得积分10
4秒前
D哈哈完成签到,获得积分10
4秒前
大意的罡完成签到,获得积分10
4秒前
封小封完成签到,获得积分10
4秒前
方方完成签到,获得积分10
5秒前
相信明天会更好完成签到,获得积分10
5秒前
zh完成签到,获得积分10
7秒前
77完成签到 ,获得积分10
7秒前
xy完成签到 ,获得积分10
8秒前
半夏完成签到,获得积分10
8秒前
solution完成签到 ,获得积分10
8秒前
李基米德完成签到,获得积分10
8秒前
9秒前
xsss完成签到,获得积分10
9秒前
41完成签到,获得积分10
9秒前
诚心的小笼包完成签到 ,获得积分10
9秒前
安详墨镜完成签到 ,获得积分10
9秒前
成永福完成签到,获得积分10
10秒前
molihuakai的应助被昨夜风宸采纳,获得10
10秒前
281911480完成签到,获得积分10
10秒前
勤恳含之完成签到 ,获得积分10
11秒前
XX完成签到 ,获得积分10
12秒前
12秒前
不知道在干嘛完成签到,获得积分10
13秒前
程xx完成签到,获得积分10
13秒前
litn完成签到 ,获得积分10
13秒前
科研民工完成签到,获得积分10
13秒前
再生极强的-涡虫完成签到,获得积分10
15秒前
15秒前
娜比小新完成签到 ,获得积分10
15秒前
晚风完成签到,获得积分10
15秒前
wq完成签到 ,获得积分10
15秒前
moca完成签到,获得积分10
16秒前
研友_Zzaoqn完成签到,获得积分10
16秒前
千空完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809184
捐赠科研通 7776198
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479039